Morgan Keegan Reports STJ 2Q11 Results

Morgan Keegan has issued a report following the second quarter results posted by St. Jude Medical STJ. According to the results, "Even with lower CRM sales than expected, St Jude Medical reported second quarter results of $1.45 billion in revenues and earnings of $0.85, both in-line with consensus and our estimates pointing to strong underlying growth in the company as a whole." STJ has an Outperform Rating and a $60 Price Target. STJ closed at $47.81 a share yesterday.